CA2875342C - Sels de desfesoterodine - Google Patents

Sels de desfesoterodine Download PDF

Info

Publication number
CA2875342C
CA2875342C CA2875342A CA2875342A CA2875342C CA 2875342 C CA2875342 C CA 2875342C CA 2875342 A CA2875342 A CA 2875342A CA 2875342 A CA2875342 A CA 2875342A CA 2875342 C CA2875342 C CA 2875342C
Authority
CA
Canada
Prior art keywords
desfesoterodine
succinate
salt
salts
solid state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2875342A
Other languages
English (en)
Other versions
CA2875342A1 (fr
Inventor
Simone EICHNER
Wolfgang Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of CA2875342A1 publication Critical patent/CA2875342A1/fr
Application granted granted Critical
Publication of CA2875342C publication Critical patent/CA2875342C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des sels de desfésotérodine pratiquement purs, des sels de desfésotérodine, leurs formes à l'état solide et des compositions pharmaceutiques comprenant un ou plusieurs des sels de desfésotérodine et/ou de leurs formes à l'état solide.
CA2875342A 2012-06-14 2013-06-14 Sels de desfesoterodine Expired - Fee Related CA2875342C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659829P 2012-06-14 2012-06-14
US61/659,829 2012-06-14
US201361818135P 2013-05-01 2013-05-01
US61/818,135 2013-05-01
PCT/US2013/045992 WO2013188829A1 (fr) 2012-06-14 2013-06-14 Sels de desfésotérodine

Publications (2)

Publication Number Publication Date
CA2875342A1 CA2875342A1 (fr) 2013-12-19
CA2875342C true CA2875342C (fr) 2017-06-13

Family

ID=48808499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875342A Expired - Fee Related CA2875342C (fr) 2012-06-14 2013-06-14 Sels de desfesoterodine

Country Status (7)

Country Link
US (1) US9315450B2 (fr)
EP (1) EP2760822B1 (fr)
CA (1) CA2875342C (fr)
ES (1) ES2569201T3 (fr)
HR (1) HRP20160363T1 (fr)
PL (1) PL2760822T3 (fr)
WO (1) WO2013188829A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017137955A1 (fr) * 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Nouveau (r) et 3-(2-(allyloxy)-5-méthylphényl)-n,n-diisopropyl-3- phénylpropan-1-amine racémique et son utilisation pour la synthèse de (r) et de 2-(3- (diisopropylamino)-1-phénylpropyl)-4-(hydroxyméthyl)phénol racémique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
DE10028443C1 (de) 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
ATE480531T1 (de) 2006-05-24 2010-09-15 Pfizer Ltd Verfahren zur herstellung von benzopyran-2- olderivaten
GB0813762D0 (en) 2008-07-28 2008-09-03 Moseley Darren C Slatted wall fixing element
PL2416761T3 (pl) 2009-05-11 2015-07-31 Ratiopharm Gmbh Desfezoterodyna w postaci soli kwasu winowego
WO2011158257A1 (fr) 2010-06-18 2011-12-22 Panacea Biotec Ltd Méthode de préparation de fesotérodine et d'intermédiaires

Also Published As

Publication number Publication date
HRP20160363T1 (hr) 2016-06-17
US9315450B2 (en) 2016-04-19
ES2569201T3 (es) 2016-05-09
EP2760822A1 (fr) 2014-08-06
PL2760822T3 (pl) 2016-09-30
EP2760822B1 (fr) 2016-03-23
CA2875342A1 (fr) 2013-12-19
WO2013188829A1 (fr) 2013-12-19
US20150152044A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
EP2791141B1 (fr) Sel de mono-tartrate de Tofacitinib
US20150232457A1 (en) Crystalline forms of afatinib di-maleate
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
EP4428129A1 (fr) Dérivé d'acide phénylpropionique substitué et son utilisation
US9221815B2 (en) Solid state form of vemurafenib choline salt
WO2023104920A1 (fr) Solvate d'acétone cristallin de la révéfénacine
CA2875342C (fr) Sels de desfesoterodine
WO2009124906A2 (fr) Procédé de préparation de monohydrate d’argatroban
US20030220389A1 (en) O-substituted 6-methyltramadol derivatives
KR20190005904A (ko) 3-[2-부틸-1-(2-디에틸아미노-에틸)-1h-벤조이미다졸-5-일]-n-하이드록시-아크릴아미드의 다형체 형태 및 그의 용도
WO2011072383A1 (fr) Procédés de purification du lubiprostone
US20250361226A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
WO2013181251A1 (fr) Sel de chlorhydrate de crizotinib sous forme cristalline
JP2023548185A (ja) クラゾセンタン二ナトリウム塩の安定な結晶性水和物
US20120178821A1 (en) Polymorphic form of toremifene citrate and process for its preparation
CN101528667A (zh) 分离得到的o-脱甲基文拉法辛的羟基和n-氧化物代谢物和衍生物以及治疗方法
EP2739610B1 (fr) Procédé de fabrication de l'ivabradine et de ses intermédiaires de synthèse
EP4073047B1 (fr) Procédé de préparation d'un dérivé d'isoindolinone, nouveaux intermédiaires utilisés pour le procédé et procédé de préparation des intermédiaires
KR101098031B1 (ko) 암로디핀 니코티네이트의 신규 결정형 및 이의 제조방법
KR20260003013A (ko) 5-{2-[벤질-(1-(4-하이드록시페닐)-1-메틸에틸)아미노]-1-하이드록시에틸}벤젠-1,3-디올헤미푸마레이트의 제조 방법
CN121548563A (zh) 3-(2,3-二氟苯氧基)氮杂环丁烷的药学上可接受的盐及其用途
NZ519130A (en) Ethers of O-desmethyl venlafaxine useful for treating central nervous system disorders
EP3558948A1 (fr) Nouveau sel d'ivabradine et utilisations de ce dernier
CA3246705A1 (fr) Intermédiaires utiles pour la préparation d'un analogue de lpxc, et leurs procédés de préparation
CN108530375A (zh) 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150330

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831